Intel stock extends gains after report of possible U.S. government stake
Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biotech company with a market capitalization of $46.57 million, reported Wednesday that its stockholders elected Srinivas Akkaraju, M.D., Ph.D., and Andrew Oxtoby as Class II directors at the company’s 2025 annual meeting, held Tuesday. Both directors will serve three-year terms ending at the 2028 annual meeting or until their successors are elected and qualified.
According to a statement based on the company’s SEC filing, Dr. Akkaraju received 14,626,646 votes in favor and 144,695 votes withheld, while Mr. Oxtoby received 14,668,424 votes in favor and 102,917 votes withheld. There were 1,328,348 broker non-votes for each nominee.
Stockholders also ratified the selection of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received 16,090,928 votes in favor, 6,975 votes against, and 1,786 abstentions.
Kalaris Therapeutics is incorporated in Delaware and is headquartered in Palo Alto, California. The company’s common stock trades on the Nasdaq Global Market under the symbol KLRS.
All information is based on a press release statement and the company’s recent filing with the Securities and Exchange Commission.
In other recent news, Kalaris has been the subject of differing analyst opinions. Piper Sandler has initiated coverage of Kalaris with a Neutral rating and a price target of $3.00, citing concerns that the preclinical data for Kalaris’s anti-VEGF treatment, TH103, does not show significant differentiation from existing standard care options for retinal diseases. In contrast, William Blair has reiterated an Outperform rating for Kalaris, maintaining a positive outlook on the company. This analysis followed discussions with Kalaris management, including CEO Andrew Oxtoby and CMO Matt Feinsod, M.D., focusing on the company’s lead asset, TH103. William Blair highlighted that TH103 is a fully humanized recombinant anti-VEGF fusion protein, which is designed to be a soluble decoy receptor with potentially greater VEGF affinity and a longer eye residence time than Eylea. These recent developments reflect the varied perspectives on Kalaris’s potential in the treatment of neovascular retinal diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.